Matsumaru, Yuji
Kitazono, Takanari
Kadota, Kazushige
Nakao, Koichi
Nakagawa, Yoshihisa
Shite, Junya
Yokoi, Hiroyoshi
Kozuma, Ken
Tanabe, Kengo
Akasaka, Takashi
Shinke, Toshiro
Ueno, Takafumi
Hirayama, Atsushi
Uemura, Shiro
Kuroda, Takeshi
Takita, Atsushi
Harada, Atsushi
Iijima, Raisuke
Murakami, Yoshitaka
Saito, Shigeru
Nakamura, Masato
Funding for this research was provided by:
Daiichi-Sankyo
Article History
Received: 23 September 2021
Accepted: 26 November 2021
First Online: 1 January 2022
Declarations
:
: Y. Matsumaru has received remuneration from Daiichi Sakyo Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. T. Kitazono has received remuneration and scholarship funds or donations from Daiichi Sakyo Co., Ltd. K. Kadota has received remuneration from Daiichi Sankyo Co., Ltd., and Sanofi K.K. K. Nakao has received remuneration from Daiichi Sankyo Co., Ltd. Y. Nakagawa has received remuneration from Bristol Myers Squibb K.K., Kowa Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Bayer Yakuhin Ltd., Sanofi K.K., Boston Scientific Corporation, and Abbott Medical Japan LLC., and research funding from Daiichi Sankyo Co., Ltd., Bayer Yakuhin Ltd., Sanofi K.K., Boston Scientific Corporation, and Abbott Medical Japan LLC. J. Shite has received remuneration from Daiichi Sankyo Co., Ltd., Nipro Corporation, Abbott Japan LLC, and Terumo Corporation. H. Yokoi has received remuneration and scholarship funds or donations from Daiichi Sankyo Co., Ltd. K. Kozuma has received remuneration and research funding from Daiichi Sankyo Co., Ltd. K. Tanabe has received remuneration from Daiichi Sankyo Co., Ltd., Sanofi K.K., AstraZeneca K.K., Abbott Medical Japan LLC., Boston Scientific Corporation, and Terumo Corporation. T. Akasaka has received remuneration from Abbot Medical Japan LLC., and Otsuka Pharmaceutical Co., Ltd., research funding from Daiichi Sankyo Co., Ltd., scholarship funds or donations from Abbot Medical Japan LLC., Nipro Corporation, and Terumo Corporation, and has a personal relationship with Terumo Corporation. T. Shinke has received remuneration and research funding from Daiichi Sankyo Co., Ltd., Bayer Yakuhin Ltd., Bristol Myers Squibb K.K., and Nippon Boehringer Ingelheim Co., Ltd. T. Ueno received consultancy fees from Japan Medical Device Technology Co., Ltd., and Nipro Corporation. A. Hirayama has received remuneration from Daiichi Sankyo Co., Ltd., Bayer Yakuhin Ltd., and Takeda Pharmaceutical Co., Ltd. S. Uemura has received remuneration from Daiichi Sankyo Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Amgen Astellas BioPharma Co., Ltd., Abbot Medical Japan LLC., Sanofi K.K., Terumo Corporation, and Bayer Yakuhin Ltd.; and research funding from Daiichi Sankyo Co., Ltd.; and scholarship funds or donations from Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Goodman Co., Ltd., Shionogi Inc., Sumitomo Dainippon Pharma Co., Ltd., Boston Scientific Japan K.K., Kaken Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharmaceutical Co., Ltd., Japan Lifeline Co., Ltd., MSD K.K., Nipro Corporation, Actelion Pharmaceuticals Japan Ltd., Pfizer Japan Inc., Abbot Medical Japan LLC., Sanofi K.K., Terumo Corporation, and Bayer Yakuhin Ltd. T. Kuroda, A. Takita, and A. Harada, are employees of Daiichi Sankyo Co., Ltd. Y. Murakami has received remuneration from SRD Co., Ltd. S. Saito has received consultancy fees from Japan Lifeline Inc., and Terumo Corporation; and remuneration from Daiichi Sankyo Co., Ltd, Abbott Medical Japan LLC., Boston Scientific Corporation, and Medtronic Japan Co., Ltd. M. Nakamura has received remuneration from Daiichi Sankyo Co., Ltd., Sanofi K.K., Terumo Corporation, and Bristol Myers Squibb K.K, and research funding from Daiichi Sankyo Co., Ltd., Sanofi K.K., and Bayer Yakuhin K.K. R. Iijima has no conflicts of interest to declare.
: The study was performed per the principles of the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects and was registered in the University hospital Medical Information Network (UMIN) Clinical Trial Registry (UMIN 000020332). The study protocol and related documents were approved by the Ethics Committee at Toho University Ohashi Medical Center on 14 December 2015 (reference code: 15-71).
: All patients provided written informed consent before study participation.